FDA Readies Proposed Rule On Combination Products Postmarket Reporting
This article was originally published in The Pink Sheet Daily
Executive Summary
A proposed rule wending its way through regulatory review would clarify adverse event reporting requirements for makers of combination products.You may also be interested in...
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
FDA Complete Response Slows Down, But Won't Stop, Lundbeck's Serdolect
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.
Krystexxa: Big Expectations For An Orphan Market
Savient's Krystexxa, an orphan drug candidate for treatment-failure gout, could bring in $600 million or more in worldwide sales by 2015, considerably bumping up the firm's potential value and making it pretty enough for picking as a potential acquisition candidate - or at the very least a collaboration partner
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: